What is Helius Medical Technologies Return-on-Tangible-Equity?
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Helius Medical Technologies's annualized net income for the quarter that ended in Mar. 2025 was $-15.35 Mil. Helius Medical Technologies's average shareholder tangible equity for the quarter that ended in Mar. 2025 was $1.17 Mil. Therefore, Helius Medical Technologies's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2025 was -1,312.70%.
The historical rank and industry rank for Helius Medical Technologies's Return-on-Tangible-Equity or its related term are showing as below:
HSDT'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -2421.57 Med: -284.54 Max: -141.09
Current: -452.51
During the past 11 years, Helius Medical Technologies's highest Return-on-Tangible-Equity was -141.09%. The lowest was -2,421.57%. And the median was -284.54%.
HSDT's Return-on-Tangible-Equity is ranked worse than 96.31% of 758
companies
in the Medical Devices & Instruments industry
Industry Median: 2.6
vs HSDT: -452.51
Helius Medical Technologies Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Helius Medical Technologies Return-on-Tangible-Equity Chart
Competitive Comparison of Helius Medical Technologies's Return-on-Tangible-Equity
For the Medical Devices subindustry, Helius Medical Technologies's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Helius Medical Technologies's Return-on-Tangible-Equity Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Helius Medical Technologies's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Helius Medical Technologies's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
Helius Medical Technologies (NAS:HSDT) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Helius Medical Technologies Return-on-Tangible-Equity Related Terms
Thank you for viewing the detailed overview of Helius Medical Technologies's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.
Helius Medical Technologies Inc is a neurotech company focused on neurological wellness. The company's purpose is to develop, license, or acquire non-invasive technologies targeted at reducing symptoms of neurological disease or trauma. The company's product, known as the Portable Neuromodulation Stimulator (PoNS) is authorized for sale in Canada as a class II, a non-implantable medical device intended for use as a short-term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury and is to be used in conjunction with supervised therapeutic exercise.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HSDT has been successfully added to your 